PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASESThe present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular,...
Specifically the composition contains a ubiquitin pathway protein binding moiety which recognizes a ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains a ubiquitin pathway ...
PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASESThe present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular,...
Disclosed are proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of IDO protein. The disclosed PROTACs typically include a first targeting moiety that binds to IDO (MIDO). The first targeting moiety typically is linked via a bond or a linker (L) to a second targeting ...
Specifically the composition contains a ubiquitin pathway protein binding moiety which recognizes a ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains a ubiquitin pathway ...
Disclosed are proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein. The disclosed PROTACs typically include a first targeting moiety that binds to c-MYC (Mc-MYC) which may be derived from a substituted heterocycle that binds to c-MYC such as a substituted ...
This technology, known as Protac, involves a chimeric molecule that could potentially recruit any cancer-causing protein to an E3 ligase for ubiquitination and subsequent degradation. In this chapter, we describe the development of this technology for cancer therapy....
Biochemistry Development of proteolysis targeting chimeric molecules (PROTACs) and studies on the biological activity of tyroscherin YALE UNIVERSITY Craig M. Crews SchneeklothAshley RobinsProteolysis Target Chimeric Molecules, or PROTACs, are heterobifunctional molecules designed to target a protein of ...
and thus can be used to prepare drugs for treating BCR-ABL and/or CRBN positive leukemia, wherein the proteolysis targeting chimeric molecule with n=3 has excellent photo-isomerization activity, and can be used in preparation of the reagents or drugs for light-regulated degradation of BCR-ABL ...
Proteolysis Targeting Chimeric molecules (Protacs) are bifunctional molecules which which can simultaneously bind a target protein and an E3 ubiquitin ligase thereby bringing the ligase and target in close proximity These bifunctional molecules allow the efficient ubiquitin transfer from the ligase complex ...